Terbute Pregnancy

• Pregnancy of Terbute in details
• Terbute breastfeeding
• Terbute reviews

Pregnancy of Terbute in details

Terbute has been shown to cross the placenta, and the fetus may experience the general adverse effects reported in the mother. Pulmonary edema has been associated with the intravenous use of Terbute in pregnant women. Myocardial necrosis in one infant was thought to be associated with Terbute given at a rate of 0.5 mg/hr for 12 weeks by subcutaneous infusion. In one retrospective review of 8,709 patients receiving continuous low-dose subcutaneous infusion of Terbute to arrest preterm labor, only 47 (0.54%) had one or more cardiopulmonary problems. Pulmonary edema was reported in 28 patients (0.32%), 17 of whom had been treated concurrently with large amounts of IV fluids or one to three tocolytic agents and four of whom had been diagnosed with pregnancy-induced hypertension and/or multiple gestation. Other cardiovascular effects occurred in 19 patients (0.22%), including electrocardiogram changes, irregular heart rate, chest pain, or shortness of breath. However, 7 of these patients had a history of cardiac problems. Use of Terbute in pregnant women for the relief of bronchospasm may interfere with uterine contractility. For the treatment of asthma, administration by metered dose inhaler results in lower plasma concentrations and consequently fewer adverse effects for the mother and fetus. Hepatitis has been reported in at least two patients receiving Terbute to control premature labor.

Terbute has been assigned to pregnancy category B by the FDA. Animal studies have failed to reveal evidence of teratogenicity. Terbute is only recommended for use during pregnancy when benefit outweighs risk.

See references

Terbute breastfeeding

Terbute is excreted in small amounts into human milk. In four mothers taking 2.5 to 5 mg per day of Terbute, milk concentrations averaged 3 to 4 ng/mL. The calculated daily dose of Terbute taken in by a nursing infant ranges from 0.2% to 0.7% of the mother's dose. Terbute is not detectable in the plasma of nursing infants and clinical signs of beta-adrenergic stimulation have not been reported. Terbute is considered be compatible with breast-feeding by the American Academy of Pediatrics.

See references

References for pregnancy information

1. Ingemarsson I, Bengtsson B "A five-year experience with Terbute for preterm labor: low rate of severe side effects." Obstet Gynecol 66 (1985): 176-80
2. Ingemarsson I, Westgren M, Lindberg C, Ahren B, Lundquist I, Carlsson C "Single injection of Terbute in term labor: placental transfer and effects on maternal and fetal carbohydrate metabolism." Am J Obstet Gynecol 139 (1981): 697-701
3. "Product Information. Brethaire (Terbute)." Novartis Pharmaceuticals, East Hanover, NJ.
4. Fletcher SE, Fyfe DA, Case CL, Wiles HB, Upshur JK, Newman RB "Myocardial necrosis in a newborn after long-term maternal subcutaneous Terbute infusion for suppression of preterm labor." Am J Obstet Gynecol 165 (1991): 1401-4
5. Quinn PG, Sherman BW, Tavill AS, Gibas AL "Terbute hepatitis in pregnancy: report of two cases and literature review." Am J Gastroenterol 89 (1994): 781-4
6. Benedetti TJ, Hargrove JC, Rosene KA "Maternal pulmonary edema during premature labor inhibition." Obstet Gynecol 59 (1982): s33-7
7. Bergman B, Bokstrom H, Borga O, Enk L, Hedner T, Wangberg B "Transfer of Terbute across the human placenta in late pregnancy." Eur J Respir Dis Suppl 134 (1984): 81-6
8. Roth AC, Milsom I, Forssman L, Ekman LG, Hedner T "Effects of intravenous Terbute on maternal circulation and fetal heart activity." Acta Obstet Gynecol Scand 69 (1990): 223-8
9. Mcdonald CF, Burdon JGW "Asthma in pregnancy and lactation - a position paper for the thoracic society of australia and new zealand." Med J Aust 165 (1996): 485-8
10. Guernsey BG, Villarreal Y, Snyder MD, Gabert HA "Pulmonary edema associated with the use of betamimetic agents in preterm labor." Am J Hosp Pharm 38 (1981): 1942-8

References for breastfeeding information

1. Lonnerholm G, Lindstrom B "Terbute excretion into breast milk." Br J Clin Pharmacol 13 (1982): 729-30
2. Roberts RJ, Blumer JL, Gorman RL, et al "American Academy of Pediatrics Committee on Drugs: Transfer of drugs and other chemicals into human milk." Pediatrics 84 (1989): 924-36
3. Mcdonald CF, Burdon JGW "Asthma in pregnancy and lactation - a position paper for the thoracic society of australia and new zealand." Med J Aust 165 (1996): 485-8
4. Boreus LO, de Chateau PU "Terbute in breast milk." Br J Clin Pharmacol 13 (1982): 731-2

References

1. DailyMed. "TERBUTALINE SULFATE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
2. PubMed Health. "Terbutaline (By injection): This section provide the link out information of drugs collectetd in PubMed Health. ". http://www.ncbi.nlm.nih.gov/pubmedhe... (accessed September 17, 2018).
3. Human Metabolome Database (HMDB). "Terbutaline: The Human Metabolome Database (HMDB) is a freely available electronic database containing detailed information about small molecule metabolites found in the human body.". http://www.hmdb.ca/metabolites/HMDB0... (accessed September 17, 2018).

Reviews

Consumer reviews

There are no reviews yet. Be the first to write one!

Your name:  Email:  Spam protection:  < Type 19 here

Information checked by Dr. Sachin Kumar, MD Pharmacology